Genden Eric M, Ferlito Alfio, Bradley Patrick J, Rinaldo Alessandra, Scully Crispian
Department of Otolaryngology-Head and Neck Surgery, Mount Sinai School of Medicine, New York, NY, USA.
Oral Oncol. 2003 Apr;39(3):207-12. doi: 10.1016/s1368-8375(02)00049-0.
While the implementation of multi-modality neoadjuvant therapy for the treatment of head and neck cancer has resulted in an improvement in local regional control, there has been a resultant increase in the reported incidence of distant metastasis. This shift in the pattern of patient treatment failure highlights the importance of identifying patients at high risk of developing metastasis, accurately detecting metastasis, and improving treatment strategies for advanced disease. Currently, metastatic lesions from head and neck primaries portend a poor prognosis; however, molecular biologic techniques offer a promising approach to the diagnosis and treatment of micrometastasis and distant metastatic lesions. The identification of tumor-specific gene mutations and the cell surface antigens may play a key role in the future management of head and neck cancer. The following review outlines just several of the current issues related to the contemporary diagnosis and management of metastatic lesions of the head and neck.
虽然多模态新辅助治疗在头颈部癌治疗中的应用已使局部区域控制得到改善,但据报道远处转移的发生率随之增加。患者治疗失败模式的这种转变凸显了识别有发生转移高风险的患者、准确检测转移以及改进晚期疾病治疗策略的重要性。目前,头颈部原发性肿瘤的转移病灶预示着预后不良;然而,分子生物学技术为微转移和远处转移病灶的诊断和治疗提供了一种有前景的方法。肿瘤特异性基因突变和细胞表面抗原的识别可能在头颈部癌的未来管理中发挥关键作用。以下综述仅概述了与头颈部转移病灶当代诊断和管理相关的几个当前问题。